Navigation Links
NUCRYST Appoints David B. Holtz as Vice President and Chief Financial Officer
Date:5/7/2008

WAKEFIELD, MA, May 7 /PRNewswire-FirstCall/ - NUCRYST Pharmaceuticals, a developer and manufacturer of medical products that fight infection and inflammation, today announced the appointment of David B. Holtz as Vice President and Chief Financial Officer, effective May 8, 2008. In these roles, Mr. Holtz will be responsible for oversight of the Controller's Group, Treasury, Risk Management and Information Technology reporting to Thomas E. Gardner, Chairman and Chief Executive Officer of NUCRYST.

"In David Holtz, we are adding a valuable asset to the senior management team at NUCRYST," said Thomas E. Gardner, Chairman and Chief Executive Officer. "David has a proven track record for helping the organizations he has worked for to generate superior value by supporting the successful execution of their business strategies. The breadth and depth of his experience in finance, accounting, compliance, cost control and business development will be of noteworthy value at this time."

Before joining NUCRYST, Mr. Holtz served as financial management consultant for various start-up companies, including Virium Pharmaceuticals, Inc. Previously he worked in various managerial roles of increasing importance at Integra LifeSciences Holdings Corporation from October 1993 through December 2006, most recently as Senior Vice President Finance. While at Integra, Mr. Holtz oversaw Integra's European operations to support the transition of acquisitions in Europe and managed all worldwide financial reporting and accounting functions. Prior to Integra, he worked for Coopers & Lybrand LLP and Cono Leasing Corporation. Mr. Holtz received a B.S. in Business Administration with an emphasis on finance from Susquehanna University and is a Certified Public Accountant.

"I am excited by the opportunity to work with Tom and the NUCRYST management team," said Mr. Holtz. "I look forward to building long-term value for NUCRYST shareholders by providing sound, disciplined financia
'/>"/>

SOURCE NUCRYST Pharmaceuticals Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. NUCRYST and Smith & Nephew Revise Agreements
2. Webcast Advisory - NUCRYST Pharmaceuticals Webcast of Conference Call to Discuss 2007 Third Quarter Results
3. NUCRYST Pharmaceuticals announces 2007 third quarter results
4. NUCRYST Pharmaceuticals announces year-end results
5. NUCRYST Announces Senior Management Change
6. NUCRYST Announces Management Realignment and R&D Portfolio Change
7. NUCRYST Announces First Quarter 2008 Financial Results
8. WorldHeart Appoints David Pellone Chief Financial Officer
9. Novo Nordisk Appoints New Leader of North American Business
10. Millstone Medical Outsourcing Appoints Operations Manager of New Memphis, TN, Facility
11. China Holdings Appoints Ronald Shon Chairman of Advisory Board to Its Wholly-Owned Subsidiary China Power, Inc.

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...ht rheumatoid arthritis, could help newly diagnose...Nov. 25 (HealthDay News) -- A drug commonly used t...ritis now also shows some promise in helping patie... drug, rituximab (Rituxan), helped patients keep p...e disease had destroyed some of their pancreatic b...
(Date:11/25/2009)...ead mothers to overlook needed care, study finds ,...- A mother,s depression can worsen her child,s ast...onth study of 262 black mothers and their children...sive symptoms had more frequent asthma symptoms, w...ptoms had less frequent asthma symptoms. , The ...
(Date:11/25/2009)...s few signs of trouble with the H1N1 vaccine, , ...The ongoing H1N1 swine flu pandemic may be driving...ger patients, a U.S. health official said Wednesda...mococcal infections around the country," Dr. Anne ...nization and Respiratory Diseases at the U.S. Cent...
(Date:11/25/2009)...RNewswire-USNewswire/--TheAmericanAssociationforHo...09,"S.2128,whichisdesignedtosubstantiallyimproveto...hebillwasintroducedbySen.GeorgeLeMieux(R-Fla.). ,...icanAssociationforHomecareoutlinedinits13-pointant...gressinFebruary.Thoseprovisionsincludecallingforre...
(Date:11/25/2009)... vaccine carried into the body on a carefully engi...uccessfully eliminate tumors in mammals, scientist...tional Medicine . , The new approach, pioneered ...rsity, uses plastic disks impregnated with tumor-s...eprogram the mammalian immune system to attack tum...
Breaking Medicine News(10 mins):Health News:Type 1 Diabetes May Have a New Foe 2Health News:Type 1 Diabetes May Have a New Foe 3Health News:Mom's Depression May Worsen Child's Asthma 2Health News:Swine Flu Tied to Rise in Pneumonias Among Young 2Health News:Swine Flu Tied to Rise in Pneumonias Among Young 3Health News:Swine Flu Tied to Rise in Pneumonias Among Young 4Health News:American Association for Homecare Endorses New U.S. Senate Bill, the 'Prevent Health Care Fraud Act of 2009' 2Health News:Implant-based cancer vaccine is first to eliminate tumors in mice 2
...le called RBP4 (retinol binding protein 4) is an i...f insulin resistance //, the main cause of type 2...bolic syndrome, according to a recent study. ...tifying individuals who are at risk of developing ...
... to develop human disease research, now proved 95 ... of extremely //complex virus - the vaccinia virus...archers at the La Jolla Institute for Allergy & Im...e to one of the most complex viruses known to man ...
... spells heaven for millions of avian influenza pat...e Children’s Research Hospital //. According to th...s potent against one antigenic variant of the avia...rus. The great thing about such vaccines is t...
...mpaign for removal of Union Health Minister Anbuma... today sought// removal of AIIMS Director P Venugo...hind the agitation by medical students in Delhi ag...nti-quota protests against 27 per reservation for ...
... of HIV positive patients in Bihar, a high profile...e legislature and those connected// with AIDS awar...d means for a more forceful drive against the drea...rces said. Top officials of National AIDS Co...
...senior BJP leader Sushma Swaraj today expressed co...ter A Ramadoss and AIIMS Director P Venugopal// , ... "I am very sad at what is happening concerni...ng there and it is churning out the best brains in...
Other Medicine News:Health News:A New Marker For Type-2 Diabetes ? 2Health News:Bioinformatics Made a Boon In Immune Response Study - LIAI Finds 2Health News:Bioinformatics Made a Boon In Immune Response Study - LIAI Finds 3Health News:Striking a Gold Mine: H5N1 Vaccine may Serve as an Antidote for Mutants and Variants 2
(Date:11/25/2009)...WATER,N.J.,Nov.25/PRNewswire/--TheFDAgrantedtradit...,anon-nucleosidereversetranscriptaseinhibitor(NNRT...useintreatment-experiencedadultswhoareexperiencing...andotherantiretroviral(ARV)agents.Thetraditionalap...nasDUET-1andDUET-2.INTELENCEiscurrentlymarketedint...
(Date:11/25/2009)...,China,Nov.25/PRNewswire-Asia-FirstCall/--ChinaSky...")(Nasdaq: CSKI ),a,leadingfullyintegratedpharmace...erdrugsinthePeople,sRepublicofChina("PRC"),today,a...onalInstitutefor,theControlofPharmaceuticalandBiol...roducts:itsDiagnosticKitforHumanProstateSpecific,A...
(Date:11/25/2009)...M,Mass.,Nov.25/PRNewswire/--AccordingtoMillenniumR...ologymarketintelligence,thenearly$3billionUSmarket...thoverthenextfiveyearsdespitetherecenteconomicslow...indsthatthismarketwillremainhighlydynamicoverthene...evicesinpreviouslyunderservedsegmentsofthetraumafi...
Breaking Medicine Technology:U.S. Food And Drug Administration (FDA) Grants Traditional Approval for INTELENCE(R) (etravirine) 2U.S. Food And Drug Administration (FDA) Grants Traditional Approval for INTELENCE(R) (etravirine) 3U.S. Food And Drug Administration (FDA) Grants Traditional Approval for INTELENCE(R) (etravirine) 4China Sky One Medical, Inc. Achieved Progress in the Development of Two New Biological Testing Kits 2China Sky One Medical, Inc. Achieved Progress in the Development of Two New Biological Testing Kits 3US Trauma Fixation Device Market Not Seeing Signs of Slowdown 2US Trauma Fixation Device Market Not Seeing Signs of Slowdown 3Mayo Clinic 26apos 3Bs Dr Denis Cortese Receives NCHL 26apos 3BS 2009 National Healthcare Leadership Award 51863 1Mayo Clinic 26apos 3Bs Dr Denis Cortese Receives NCHL 26apos 3BS 2009 National Healthcare Leadership Award 51863 2Mayo Clinic 26apos 3Bs Dr Denis Cortese Receives NCHL 26apos 3BS 2009 National Healthcare Leadership Award 51863 3Mayo Clinic 26apos 3Bs Dr Denis Cortese Receives NCHL 26apos 3BS 2009 National Healthcare Leadership Award 51863 4Shire Receives Fast Track Designation for velaglucerase alfa for Gaucher Disease 4730 1Shire Receives Fast Track Designation for velaglucerase alfa for Gaucher Disease 4730 2Shire Receives Fast Track Designation for velaglucerase alfa for Gaucher Disease 4730 3Shire Receives Fast Track Designation for velaglucerase alfa for Gaucher Disease 4730 4Frost 26 Sullivan 3A North American Government Biometrics Markets Thrive With Active R 26D Thrust 9273 1Frost 26 Sullivan 3A North American Government Biometrics Markets Thrive With Active R 26D Thrust 9273 2Frost 26 Sullivan 3A North American Government Biometrics Markets Thrive With Active R 26D Thrust 9273 3Frost 26 Sullivan 3A North American Government Biometrics Markets Thrive With Active R 26D Thrust 9273 4
... certain mutations enable specific cells in the,re...hat suggests deliberate,genetic manipulations migh..., Tenn., Oct. 18 Investigators at St.,Jude Childr...at gives rise,to the eye cancer retinoblastoma, di... and development. The finding suggests for the fir...
...World Muscle Society International Congress, SOUT....,(PTC), a biopharmaceutical company focused on th...small-molecule drugs targeting,post-transcriptiona...ata,from a Phase 2 clinical trial of PTC124 in pat...o a nonsense mutation. The results, which include ...
Other Medicine Technology:St. Jude Identifies the Specific Cell That Causes Eye Cancer, Disproving Long-Held Theory 2St. Jude Identifies the Specific Cell That Causes Eye Cancer, Disproving Long-Held Theory 3PTC Therapeutics Announces Additional Results from Phase 2 Study of PTC124 in Duchenne Muscular Dystrophy 2PTC Therapeutics Announces Additional Results from Phase 2 Study of PTC124 in Duchenne Muscular Dystrophy 3PTC Therapeutics Announces Additional Results from Phase 2 Study of PTC124 in Duchenne Muscular Dystrophy 4
...pinal Implant system. Material that has a modulus ... The result is an implant that meets the structura...ptimizing the fusion environment through an open, ...gn with 5 and 10 degrees of lordosis. Minimal inst...
...em provides anterior column support for single or ...rom T1 to L5. The system consists of one or more P... a desired height, accommodating various patient n...erial emulates the biomechanical properties of hum...
Rotafix Intervertebral Cage
Miniflex
Medicine Products: